CFPAC-1 (ATCC® CRL-1918)

Organism: Homo sapiens, human  /  Cell Type: Epithelial  /  Tissue: pancreas; derived from metastatic: liver  /  Disease: ductal adenocarcinoma; cystic fibrosis

Organism Homo sapiens, human
Tissue pancreas; derived from metastatic: liver
Cell Type Epithelial
Product Format frozen
Morphology epithelial
Culture Properties adherent
Biosafety Level 1
Disease ductal adenocarcinoma; cystic fibrosis
Age 26 years
Gender male
Ethnicity Caucasian
Applications This cell line is a suitable transfection host.
Storage Conditions liquid nitrogen vapor phase
Karyotype hyperdiploid; modal number = 73; range = 65 to 75; several translocations were evident; two to three apparently normal copies of number 7 (to which the cystic fibrosis gene has been mapped) were present in every metaphase examined
Derivation
This line was derived from a ductal adenocarcinoma (liver metastasis) from a patient with cystic fibrosis.
Clinical Data
26 years
Caucasian
male
Antigen Expression
CA19-9 antigen, 12000 units/mL, epithelial keratins
Genes Expressed
carcinoembryonic antigen (CEA), 9 ng/mL; pancreatic oncofetal antigen (POA), 28 ng/mL; adenocarcinoma associated antigen (ACAA), 5000 ng/mL; CA 19-9 antigen, 12000 units/mL; epithelial keratins
Cellular Products
carcinoembryonic antigen (CEA), 9 ng/mL; pancreatic oncofetal antigen (POA), 28 ng/mL; adenocarcinoma associated antigen (ACAA), 5000 ng/mL; CA 19-9 antigen, 12000 units/mL; epithelial keratins
Tumorigenic Yes
Effects
Yes, in nude mice (passage 34)
Comments
The cells exhibit ion transport activities consistent with cystic fibrosis and express the product of the CF gene (cystic fibrosis transmembrane regulator, CFTR).
CFPAC-1 cells show no effect of cAMP agonists, adenyl cyclase stimulators or phosphodiesterase inhibitors on Cl- flux, but do respond to Ca++ ionophores with increase Cl- efflux.
The cells have the most common form of the CF mutation, deletion of three nucleotides resulting in the absence of phenylalanine at position 508.
CFPAC-1 cells have epithelial morphology and polarization with apical microvilli, tight junctions and gap junctions.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Volumes are given for a 75 cm2 flask. Increase or decrease the amount of dissociation medium needed proportionally for culture vessels of other sizes.
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:10 is recommended
Medium Renewal: Every 2 to 3 days
Cryopreservation
Freeze Medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage Temperature: Liquid nitrogen vapor phase
Culture Conditions
Atmosphere: Air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C
STR Profile
Amelogenin: X,Y
CSF1PO: 10
D13S317: 12
D16S539: 9,11
D5S818: 10,11
D7S820: 8,10
THO1: 8
TPOX: 8
vWA: 17
Population Doubling Time 32 hrs
Name of Depositor RA Schoumacher
References

Schoumacher RA, et al. A cystic fibrosis pancreatic adenocarcinoma cell line. Proc. Natl. Acad. Sci. USA 87: 4012-4016, 1990. PubMed: 1692630

McIntosh JC, et al. Pancreatic adenocarcinoma in a patient with cystic fibrosis. Am. J. Med. 85: 592, 1988. PubMed: 3177424

Basic Documentation
Other Documentation
References

Schoumacher RA, et al. A cystic fibrosis pancreatic adenocarcinoma cell line. Proc. Natl. Acad. Sci. USA 87: 4012-4016, 1990. PubMed: 1692630

McIntosh JC, et al. Pancreatic adenocarcinoma in a patient with cystic fibrosis. Am. J. Med. 85: 592, 1988. PubMed: 3177424